This study has 8 locations in USA - 11 Dec `20Evaluation of AMG 714 for Vitiligo (REVEAL)

Official title: Evaluation of AMG 714 for Vitiligo: A Phase 2a Randomized Double Blind Placebo Controlled Trial (ITN086AI)

The AMG 714 for Vitiligo (REVEAL Trial), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), is a Phase 2 clinical study evaluating the efficacy and safety of AMG 714, an anti-IL-15 monoclonal antibody, in adults with vitiligo. The trial aims to determine if AMG 714, combined with narrowband ultraviolet B (nbUVB) phototherapy, can effectively restore skin pigmentation by modulating the immune response responsible for melanocyte destruction.

This is an active study which is not recruiting new patients.

 

Start date: 2020-12-11

Completion date: 2025-05-30

Contact: Brett A. King, MD, PhD

Tel.:

Email:

Link: https://clinicaltrials.gov/study/NCT04338581

Clinical Trials Alerts

Sign up and be the first to know when new trials are starting nearby.



FAQOther Questions

  • How Vitiligo Changes with Age?

    Vitiligo, a condition characterized by the loss of skin pigmentation, can affect individuals at any stage of life. While it often appears before the age of 20, its progression a...

  • What tests for vitiligo should be done?

    Before starting vitiligo therapy, several tests may be recommended to ensure an accurate diagnosis and appropriate treatment plan: Physical Examination A thorough physical exa...

  • Can Ayurveda help with vitiligo?

    Vitiligo is an autoimmune condition characterized by white patches of skin that can develop and spread unpredictably. While there is no cure, medical treatments and complementar...